These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 29250254)

  • 21. Quality of clinical direct oral anticoagulant prescribing and identification of risk factors for inappropriate prescriptions.
    Zhang ZX; van de Garde EMW; Söhne M; Harmsze AM; van den Broek MPH
    Br J Clin Pharmacol; 2020 Aug; 86(8):1567-1574. PubMed ID: 32090369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
    Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Nadkarni A; Shank TC
    BMC Cardiovasc Disord; 2019 Jun; 19(1):142. PubMed ID: 31195999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study.
    Lawal OD; Aronow HD; Shobayo F; Hume AL; Taveira TH; Matson KL; Zhang Y; Wen X
    Circulation; 2023 Mar; 147(10):782-794. PubMed ID: 36762560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 25. Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants.
    Baker CL; Dhamane AD; Rajpura J; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Lin J
    Clin Appl Thromb Hemost; 2019; 25():1076029619870249. PubMed ID: 31418293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation.
    Jackevicius CA; Lu L; Ghaznavi Z; Warner AL
    Circ Cardiovasc Qual Outcomes; 2021 Feb; 14(2):e007230. PubMed ID: 33541109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.
    Dhamane AD; Ferri M; Keshishian A; Russ C; Atreja N; Gutierrez C; Emir B; Yuce H; Di Fusco M
    Adv Ther; 2023 Mar; 40(3):887-902. PubMed ID: 36527598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns and outcomes of switching direct oral anticoagulants in non-valvular atrial fibrillation: A real-world experience from Spain.
    Rodilla E; Orts-Martínez MI; Sanz-Caballer MA; Gimeno-Brosel MT; Arilla-Morel MJ; Navarro-Gonzalo I; Castillo-Valero I; Salvador-Mercader I; Carral-Tatay A
    Rev Clin Esp (Barc); 2023; 223(6):340-349. PubMed ID: 37105383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and factors associated with inappropriate dosing of apixaban and rivaroxaban in hospitalized older adults with atrial fibrillation: a cross-sectional study.
    Decaix T; Kemache K; Gay P; Laprévote O; Ketz F; Pautas É
    Drugs Aging; 2024 Jan; 41(1):55-64. PubMed ID: 37957440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review.
    Bikdeli B; Zahedi Tajrishi F; Sadeghipour P; Talasaz AH; Fanikos J; Lippi G; Siegal DM; Eikelboom JW; Monreal M; Jimenez D; Connors JM; Ageno W; Barnes GD; Piazza G; Angiolillo DJ; Parikh SA; Kirtane AJ; Lopes RD; Bhatt DL; Weitz JI; Mehran R; Krumholz HM; Goldhaber SZ; Lip GYH
    JAMA Cardiol; 2022 Jul; 7(7):747-759. PubMed ID: 35648414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity.
    Russo V; Cattaneo D; Giannetti L; Bottino R; Laezza N; Atripaldi U; Clementi E
    Clin Ther; 2021 Sep; 43(9):e255-e263. PubMed ID: 34366151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
    Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
    Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective Comparison of Patients ≥ 80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral Anticoagulant.
    Taoutel R; Ezekowitz MD; Chaudhry UA; Weber C; Hassan D; Gracely EJ; Kamareddine MH; Horn BI; Harper GR
    Int J Cardiol Heart Vasc; 2022 Dec; 43():101130. PubMed ID: 36246771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation.
    Jansson M; Själander S; Sjögren V; Renlund H; Norrving B; Själander A
    Thromb Res; 2020 Jan; 185():135-141. PubMed ID: 31816553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis.
    Shen NN; Zhang C; Hang Y; Li Z; Kong LC; Wang N; Wang JL; Gu ZC
    Front Pharmacol; 2021; 12():581293. PubMed ID: 34122056
    [No Abstract]   [Full Text] [Related]  

  • 36. [One-year persistence of patients already treated with oral anticoagulants for atrial fibrillation].
    Simonyi G; Ferenci T; Finta E; Gasparics R; Medvegy M
    Orv Hetil; 2019 Mar; 160(13):509-515. PubMed ID: 30907102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [ANMCO Position paper: Prescription appropriateness of direct oral anticoagulants for stroke and systemic thromboembolis with non-valvular atrial fibrillation].
    Mocini D; Di Fusco SA; De Luca L; Caldarola P; Cipriani M; Corda M; Di Lenarda A; De Nardo A; Francese GM; Napoletano C; Navazio A; Riccio C; Roncon L; Tizzani E; Urbinati S; Valente S; Gulizia MM; Gabrielli D; Oliva F; Colivicchi F
    G Ital Cardiol (Rome); 2021 Dec; 22(12):1024-1033. PubMed ID: 34845405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prescribing Patterns of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Retrospective Cohort Analysis.
    Reyes JL; Herzog CA; Yan H; Roetker NS; Wetmore JB
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221142220. PubMed ID: 36472155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints.
    Zielinski GD; Teichert M; Klok FA; Rosendaal FR; Huisman MV; Cannegieter SC; Lijfering WM
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1371-1378. PubMed ID: 30443944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
    J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.